Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457562 | 0.79 | KMT2A (0.47) | CYP19A1MAOAMAOBNPC1GFER | |
| SCHEMBL2457565 | 0.79 | KMT2A (0.47) | CYP19A1MAOAMAOBNPC1GFER | |
| SCHEMBL2774526 | 0.76 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL2774532 | 0.76 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL29664559 | 0.76 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL13503135 | 0.75 | ALDH1A1 (0.36) | NPC1MAPTNPSR1 | |
| SCHEMBL11288405 | 0.72 | CYP19A1 (0.91) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL11288404 | 0.72 | CYP19A1 (0.91) | CYP19A1MAOAMAOBNPC1MAPT | |
| SCHEMBL10481989 | 0.71 | LCK (0.61) | CYP19A1MAOAMAOB | |
| SCHEMBL10481928 | 0.71 | NPC1 (0.34) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | claimed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | claimed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | claimed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1723132-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, TBXA2R | CYP19A1 1976/4885MAOA 2900/4885MAOB 2969/4885 |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PTGER3, PTGER4, PTGES3 | CYP19A1 1055/4885MAOA 3187/4885MAOB 3304/4885 |
| US-20100261760-A1 | EP2 Receptor Agonists | PTGER2, PTGER1, TBXA2R | CYP19A1 1976/4885MAOA 2900/4885MAOB 2969/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | CYP19A1 1061/4885MAOA 3350/4885MAOB 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.